First Biosimilar, a Filgrastim Copycat, Is Approved
(MedPage Today) -- Zarxio will compete against Amgen's Neupogen, but price impact still unclear.
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Filgrastim | Health | International Medicine & Public Health | Neulasta | Neupogen